Making genetic risk predictions more accurate for adults with acute myeloid leukemia
Towards an inclusive genomic risk classification for acute myeloid leukemia (AML)
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11164532
This project is developing better genetic-based risk categories to help guide treatment decisions for adults with acute myeloid leukemia.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11164532 on ClinicalTrials.gov |
What this research studies
Researchers will analyze large-scale tumor and inherited (germline) genetic data from adults with AML to see how a patient’s genetic background changes the meaning of common AML mutations. They will use statistical and computational methods to refine which gene changes predict outcomes across diverse populations and to find previously unrecognized genetic features that may drive disease or therapy resistance. The team aims to produce a more inclusive molecular risk classification so doctors can match treatment intensity more accurately to each patient. This work focuses on data analysis and genetics rather than testing new drugs.
Who could benefit from this research
Good fit: Adults (age 21 and older) diagnosed with acute myeloid leukemia, particularly those who can provide genetic samples or allow their clinical and genomic data to be used, are the ideal candidates.
Not a fit: Children and teenagers under 21 and patients looking for an immediate experimental therapy are unlikely to receive direct treatment benefit from this genetics-focused project.
Why it matters
Potential benefit: If successful, this could lead to more accurate, personalized treatment choices and better outcome predictions for adults with AML.
How similar studies have performed: Large genomic studies have already shaped current AML risk categories, but adjusting risk predictions based on patients' inherited genetic backgrounds is a newer and less-tested approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EISFELD, ANN-KATHRIN — OHIO STATE UNIVERSITY
- Study coordinator: EISFELD, ANN-KATHRIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.